ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline is boosting its cancer therapy pipeline by paying Merck KGaA about $340 million to jointly develop and commercialize a cancer immunotherapy from the German firm. The experimental therapy, bintrafusp alfa, is a fusion protein that targets two pathways used by cancer cells to suppress the immune system: transforming growth factor-β and programmed cell death ligand-1 (PD-L1). Anti-PD-L1 antibodies are part of an increasingly lucrative class of cancer drugs that firms are looking to combine with other therapies. Merck could earn up to $3.9 billion in future milestone payments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter